Zentalis + Gemzar
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Pancreatic Adenocarcinoma
Conditions
Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Trial Timeline
Nov 16, 2023 → Jun 1, 2027
NCT ID
NCT06015659About Zentalis + Gemzar
Zentalis + Gemzar is a phase 2 stage product being developed by Zentalis Pharmaceuticals for Advanced Pancreatic Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT06015659. Target conditions include Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06015659 | Phase 2 | Active |
Competing Products
20 competing products in Advanced Pancreatic Adenocarcinoma